Shares of Glenmark Pharma rose 1.7 percent intraday Tuesday after company received USFDA approval for Telmisartan and Hydrochlorothiazide tablets.
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg, a generic version of Micardis HCT Tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.
For the 12 month period ending January 2019, the Micardis HCT Tablets market achieved annual sales of approximately USD 40.6 million, as per IQVIATM sales data.
Glenmark’s current portfolio consists of 150 products authorized for distribution in the US marketplace and 52 ANDA’s pending approval with the USFDA.
